Our capabilities extend far beyond conventional analysis. Through the integration of diverse multi-omics platforms, ranging from genetics to transcriptomics and even advanced techniques like single-cell sequencing, we can comprehensively characterize the tumor and its microenvironment, and identify molecular profiles associated with clinical outcome and therapeutic vulnerabilities. Our focus extends beyond the tumor itself; we are deeply intrigued by the germline, as certain tumors may harbor hidden predispositions to cancer development. By identifying these germline alterations, exciting opportunities for targeted therapies can arise. Moreover, our partnerships enable us to access tumor profiling services, including full Exome and Transcriptome sequencing. In addition to our multiomic analysis, we have a complementary tool at our disposal: patient-derived organoids. These remarkable structures retain the three-dimensional architecture of the tumor, faithfully replicating its biological and molecular characteristics in culture. Through these patient-derived organoids and patient-derived xenografts, we can experimentally validate potential therapeutic avenues before administering them to the patient, offering innovative opportunities for patients afflicted by malignant brain tumors.